| Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial E Ellebaek, L Engell-Noerregaard, TZ Iversen, TM Froesig, S Munir, ... Cancer Immunology, Immunotherapy 61, 1791-1804, 2012 | 150 | 2012 |
| Aberrant expression of MHC class II in melanoma attracts inflammatory tumor-specific CD4+ T-cells, which dampen CD8+ T-cell antitumor reactivity M Donia, R Andersen, JW Kjeldsen, P Fagone, S Munir, F Nicoletti, ... Cancer research 75 (18), 3747-3759, 2015 | 118 | 2015 |
| HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients S Munir, GH Andersen, Ö Met, M Donia, TM Frøsig, SK Larsen, ... Cancer Research 73 (6), 1764-1776, 2013 | 96 | 2013 |
| The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy MO Holmström, E Martinenaite, SM Ahmad, Ö Met, C Friese, L Kjær, ... Leukemia 32 (2), 429-437, 2018 | 83 | 2018 |
| CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment E Martinenaite, S Munir Ahmad, M Hansen, Ö Met, MW Westergaard, ... Oncoimmunology 5 (11), e1238541, 2016 | 76 | 2016 |
| The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells S Munir, GH Andersen, IM Svane, MH Andersen Oncoimmunology 2 (4), e23991, 2013 | 73 | 2013 |
| The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms MO Holmström, MD Hjortsø, SM Ahmad, Ö Met, E Martinenaite, C Riley, ... Leukemia 31 (2), 495-498, 2017 | 58 | 2017 |
| Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells S Munir, GH Andersen, A Woetmann, N Ødum, JC Becker, MH Andersen Leukemia 27 (11), 2251-2253, 2013 | 54 | 2013 |
| Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase S Munir, SK Larsen, TZ Iversen, M Donia, TW Klausen, IM Svane, ... PLoS One 7 (4), e34568, 2012 | 54 | 2012 |
| Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway SM Ahmad, SK Larsen, IM Svane, MH Andersen Leukemia 28 (1), 236-238, 2014 | 46 | 2014 |
| Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNγ signaling M Donia, K Harbst, M van Buuren, P Kvistborg, MF Lindberg, R Andersen, ... Cancer Research 77 (17), 4562-4566, 2017 | 44 | 2017 |
| PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine S Munir Ahmad, E Martinenaite, M Hansen, N Junker, TH Borch, Ö Met, ... Oncoimmunology 5 (8), e1202391, 2016 | 41 | 2016 |
| The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy SM Ahmad, E Martinenaite, M Holmström, MA Jørgensen, Ö Met, ... Oncoimmunology 7 (2), e1390641, 2018 | 35 | 2018 |
| The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity SM Ahmad, IM Svane, MH Andersen Blood cancer journal 4 (7), e230-e230, 2014 | 35 | 2014 |
| Functional characterization of Foxp3-specific spontaneous immune responses SK Larsen, S Munir, A Woetmann, TM Frøsig, N Odum, IM Svane, ... Leukemia 27 (12), 2332-2340, 2013 | 34 | 2013 |
| High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals MO Holmström, SM Ahmad, U Klausen, SK Bendtsen, E Martinenaite, ... Blood cancer journal 9 (2), 8, 2019 | 33 | 2019 |
| Tryptophan 2, 3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer MD Hjortsø, SK Larsen, P Kongsted, Ö Met, TM Frøsig, GH Andersen, ... Oncoimmunology 4 (1), e968480, 2015 | 31 | 2015 |
| Frequent adaptive immune responses against arginase-1 E Martinenaite, REJ Mortensen, M Hansen, M Orebo Holmström, ... Oncoimmunology 7 (3), e1404215, 2018 | 28 | 2018 |
| Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma E Blümel, S Munir Ahmad, C Nastasi, A Willerslev-Olsen, M Gluud, ... Oncoimmunology 9 (1), 1751561, 2020 | 27 | 2020 |
| PD-L1-specific T cells SM Ahmad, TH Borch, M Hansen, MH Andersen Cancer immunology, immunotherapy 65, 797-804, 2016 | 26 | 2016 |
